Skip to main content

Myelodysplastic Diseases News

Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for Tibsovo solidifies Servier's leadership in mutant IDH...

Space Travel Takes Toll on Astronauts' Blood, Bone

WEDNESDAY, Aug. 23, 2023 – When astronauts travel to space, the experience depletes their red blood cells and bone, according to a new study. Fortunately, it appears their bodies can eventually...

Misdiagnosis Common for Suspected Myelodysplastic Neoplasms

FRIDAY, Aug. 11, 2023 – For patients with suspected myelodysplastic neoplasms (MDS), diagnoses are often discordant for local clinical sites and central, adjudicated review, according to a study...

FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine)...

Ask a question

To post your own question to this support group, sign in or create an account.